Home > Insider Trading > Astrazeneca Plc

Astrazeneca Plc (AZN)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
231 - 240
Next >>

AstraZeneca plc (ADR) (AZN) CEO Claims The Drug Approval Process Of NHS Is Counterproductive

AstraZeneca plc (ADR) (NYSE:AZN)’s chief executive officer has said that the long negotiation process that the NHS undertakes with drugmakers before approving medications is making it hard for patients...

Keep Reading →

December 30th, 2016 - News Stock Analysis

10 Famous Corporate Whistleblowers in Publicly-Traded Companies

It takes a lot of guts for an individual to stand up against huge corporate entities for the overall well-being of the society.

Keep Reading →

December 30th, 2016 - Lists News

How AstraZeneca plc (ADR) (AZN) Stacks Up Against Its Peers

At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively...

Keep Reading →

December 9th, 2016 - Hedge Funds News

AstraZeneca PLC (ADR) (AZN) Cuts Jobs, Signs New Collaboration With Eli Lilly And Co (LLY)

“By diligently prioritizing, we will continue to successfully launch and commercialize new medicines, meet the needs of our customers and patients, and ultimately help AstraZeneca return to growth,” ...

Keep Reading →

December 9th, 2016 - News Stock Analysis

Can AstraZeneca Plc (AZN) Lung Cancer Pill Take Over Chemo Treatment?

Tagrisso, a lung cancer med from AstraZeneca plc (ADR) (NYSE:AZN) is already in early approval based on mid-stage studies, which demonstrates the possibility of it replacing the standard chemotherapy ...

Keep Reading →

December 7th, 2016 - News Stock Analysis

AstraZeneca PLC (ADR) (AZN) Relocating Jobs At U.K. Division

AstraZeneca plc (ADR) (NYSE:AZN) plans to cut some back office jobs in the U.K. as the company works toward cost-cutting and operation consolidation. The latest job cut by the company in the U.K.

Keep Reading →

December 6th, 2016 - News Stock Analysis

AstraZeneca PLC (ADR) (AZN), Ranbaxy Laboratories Limited (ADR) (RBXLY) Wins Over Illegal Deal Case

The 1st US Circuit Court of Appeals has recently ruled in favor of AstraZeneca plc (ADR) (NYSE:AZN) and Ranbaxy Laboratories Limited (ADR) (OTCMKTS:RBXLY) on a long-lasting class action lawsuit involving...

Keep Reading →

November 23rd, 2016 - News Stock Analysis

AstraZeneca PLC (ADR) (AZN) Retreats On Some Durvalumab Plans

AstraZeneca PLC (ADR) (NYSE:AZN) will no longer seek early regulatory review of its drug candidate durvalumab in patients with head and neck cancers.

Keep Reading →

November 11th, 2016 - Earnings Report News Stock Analysis

AstraZeneca PLC (ADR) (AZN) Unveils Positive SOLO-2 Data

AstraZeneca plc (ADR) (NYSE:AZN) has recently released encouraging data from SOLO-2, a phase 3 clinical trial evaluating the efficacy of Lynparza (olaparib) as a monotherapy for the maintenance treatment...

Keep Reading →

October 27th, 2016 - News Stock Analysis

AstraZeneca Plc (ADR) (AZN) Offloads Two Diabetes Drugs to Focus on Core Therapeutic Areas

AstraZeneca Plc (ADR) (NYSE:AZN) has once again reiterated its intention to focus on core therapeutic areas with the signing of a new commercialization agreement with a subsidiary of 3SBio, in China.

Keep Reading →

October 14th, 2016 - News Stock Analysis